Correlation between factors involved in the local haemostasis and angiogenesis in full term human placenta.
BACKGROUND
Few studies have been carried out to investigate whether distinct areas of full term placenta express different amounts of markers involved in the placental haemostasis and angiogenesis. A possible relationship between the expression of genes involved in the haemostasis and angiogenesis of human placenta has not been investigated.


METHODS
Twenty-eight fresh human placentas (35-41 weeks of gestation) from uneventful pregnancies were dissected with two different methods. Quantitative mRNA expression of the tissue factor (TF), TF pathway inhibitor (TFPI), TFPI-2, plasminogen activator inhibitor (PAI-2), annexin V (Anx V), vascular endothelial growth factor (VEGF), and thrombomodulin (TM) genes was evaluated by quantitative real time PCR system. Histology of each sample was graded.


RESULTS
Gene expression of all the considered markers was not significantly different in each area, using both the different methods of dissection. A significant correlation (p<0.05) was found between the expression of TF and TFPI-2. TF and TFPI-2 were significantly (p<0.05) associated with VEGF, whereas a stronger association (p<0.01) was found between TFPI and TFPI-2. TFPI and TFPI-2 were strongly associated with PAI-2 expression (p<0.01).


CONCLUSIONS
In placentas with central cord insertion, gene expression is not dependent on the method of sampling site. A significant relationship between haemostasis and angiogenesis in at term placentas was shown.
Chinni
Elena
E
Atherosclerosis and Thrombosis Unit, I.R.C.C.S. Casa Sollievo della Sofferenza, S. Giovanni R (FOGGIA), Italy.
Colaizzo
Donatella
D
Margaglione
Maurizio
M
Rubini
Corrado
C
D'Ambrosio
Rosa Lucia
RL
Giuliani
Francesco
F
Di Vagno
Giovanni
G
Grandone
Elvira
E
D017304:Annexin A5 / Q000235:genetics / Q000378:metabolism; D005260:Female; D015870:Gene Expression / Q000502:physiology; D006023:Glycoproteins / Q000235:genetics / Q000378:metabolism; D006487:Hemostasis / Q000502:physiology*; D006801:Humans; D008074:Lipoproteins / Q000235:genetics / Q000378:metabolism; D018919:Neovascularization, Physiologic / Q000502:physiology*; D010920:Placenta / Q000098:blood supply* / Q000166:cytology / Q000502:physiology*; D017396:Plasminogen Activator Inhibitor 2 / Q000235:genetics / Q000378:metabolism; D011247:Pregnancy; D012333:RNA, Messenger / Q000378:metabolism; D018180:Thrombomodulin / Q000235:genetics / Q000378:metabolism; D013925:Thromboplastin / Q000235:genetics / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics / Q000378:metabolism
D017304:Annexin A5; D006023:Glycoproteins; D008074:Lipoproteins; D017396:Plasminogen Activator Inhibitor 2; D012333:RNA, Messenger; D018180:Thrombomodulin; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C051928:lipoprotein-associated coagulation inhibitor; C021240:tissue-factor-pathway inhibitor 2; D013925:Thromboplastin